What kidney risk is associated with combining tenofovir disoproxil fumarate with a ritonavir- or cobicistat-boosted protease inhibitor?

Combining tenofovir disoproxil fumarate with a ritonavir- or cobicistat-boosted protease inhibitor is associated with a higher reported risk of renal impairment, requiring close renal monitoring and careful evaluation in patients with renal risk factors.